Survival After Blood Transfusion in the French Administrative Regions of Burgundy and Franche-Comté (STeF-BFC)
|ClinicalTrials.gov Identifier: NCT02852993|
Recruitment Status : Completed
First Posted : August 2, 2016
Last Update Posted : August 2, 2016
Red blood cell transfusion (RBC) is the main symptomatic treatment for severe anemia. RBC transfusion has proven its efficacy regarding mortality and morbidity, but it is not without side effects. The infectious side effects of transfusion are largely considered under control, non-infectious side effects are taking center stage. Seeking explanations for the beneficial and deleterious effects of RBC transfusions is necessary to ensure the safe and optimal use of this precious resource.
The investigators aim to study the impact of donor and RBC characteristics on patient survival.
|Condition or disease|
|Erythrocyte Transfusion for All Conditions|
|Study Type :||Observational|
|Actual Enrollment :||16099 participants|
|Official Title:||Survival After Blood Transfusion in the French Administrative Regions of Burgundy and Franche-Comté|
|Study Start Date :||September 2013|
|Actual Primary Completion Date :||June 2015|
|Actual Study Completion Date :||June 2015|
A cohort of patients receiving erythrocyte transfusion for the first time at the CHU Besançon or CHU Dijon during the study period.
- Survival [ Time Frame: 12 months ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02852993
|Centre d'Investigation Clinique, CHU de Besançon|
|Besançon, France, 25030|
|Département d'information Médicale, CHU Dijon|
|Dijon, France, 21079|
|Principal Investigator:||Maxime Desmarets, MD, PhD||Centre d'Investigation Clinique; CHU Besançon|